4//SEC Filing
Chang David D 4
Accession 0001593968-24-000192
CIK 0001737287other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 5:42 PM ET
Size
9.6 KB
Accession
0001593968-24-000192
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Common Stock
2024-01-25+317,800→ 4,513,203 total - Award
Stock Option (Right to buy)
2024-01-25+1,123,535→ 1,123,535 totalExercise: $3.20Exp: 2034-01-25→ Common Stock (1,123,535 underlying)
Holdings
- 1,201,108(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Includes 1492 shares of the Issuer's common stock acquired by the reporting person on September 15,2023 pursuant to an employee stock purchase program.
- [F2]Securities held in the name of the Chang 2006 Family Trust
- [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F5]1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.
Documents
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001611024
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 5:42 PM ET
- Size
- 9.6 KB